



Robert Greene Sterne Jorge A. Goldstein David K.S. Cormwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Juffrey T. Helvey Eldora L. Ellison
Donald R. Banowit
Peter A. Jackman
Brian J. Del Buono
Mark Fox Evens
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Edward W. Yee
Virgil Lee Beaston
Theodore A. Wood
Joseph S. Ostroff
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis

Ann E. Summerfield Helene C. Carlson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Bashir M.S. Ali Shannon A. Carroll Anbar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou Young Tang Christopher J. Walsh W. Blake Coblentz*
James J. Pohl
John T. Haran
Mark W. Ryglel
Michael R. Malek*
Carla Ji-Eun Kim
Doyle A. Siever*
Alexandra K. Pechhold
C. Matthew Rozier*
Robert A. Schwartzman
Bryan L. Skelkon*

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach Julie A. Heider Mita Mukherjee Scott M. Woodhouse Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer Aaron S. Lukas Gaurav Asthana

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie

*Admitted only in Maryland * Admitted only in Virginia •Practice Limited to Federal Agencies

March 20, 2007

WRITER'S DIRECT NUMBER:
(202) 772-8625
INTERNET ADDRESS:
ESTEFFE@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450 Art Unit 1633

Attn: Mail Stop Amendment

Re:

U.S. Utility Patent Application

Application No. 10/618,299; Filed: July 11, 2003

For: Method of Enhancing Delivery of a Therapeutic Nucleic Acid

Inventors: Barsoum et al.

Our Ref: 2159.0830001/EJH/SAS

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Reply to Notice of Non-Compliant Amendment Under 37 C.F.R. § 1.121; and
- 2. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe

Attorney for Applicants Registration No. 36,688

EKS/EJH/SAS/dms Enclosures

653923_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Barsoum et al.

Appl. No.: 10/618,299

Filed: July 11, 2003

For: Method of Enhancing Delivery of a

Therapeutic Nucleic Acid

Confirmation No.: 6907

Art Unit: 1633

Examiner: Robert M. Kelly

Atty. Docket: 2159.0830001/EJH/SAS

Reply to Notice of Non-Compliant Amendment (37 C.F.R. § 1.121)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Notice of Non-Compliant Amendment dated March 9, 2007, Applicants submit the following corrected Amendment and Reply. Claims 65-66 were incorrectly labeled as claims 67-68 in the Amendment and Reply originally filed on December 18, 2006. Applicants apologize for any confusion. A corrected copy of the *Amendments to the Claims* section begins at page 2, with claims 65-66 now correctly numbered. A corrected copy of the *Remarks* section is also submitted herewith beginning at page 8, with remarks now referring to the proper claim numbers.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.